Cargando…

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview

Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relev...

Descripción completa

Detalles Bibliográficos
Autores principales: Verghese, Naina R., Barrenetxea, Jon, Bhargava, Yukti, Agrawal, Sagun, Finkelstein, Eric Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461095/
https://www.ncbi.nlm.nih.gov/pubmed/31007877
http://dx.doi.org/10.1080/20016689.2019.1601060
_version_ 1783410443592663040
author Verghese, Naina R.
Barrenetxea, Jon
Bhargava, Yukti
Agrawal, Sagun
Finkelstein, Eric Andrew
author_facet Verghese, Naina R.
Barrenetxea, Jon
Bhargava, Yukti
Agrawal, Sagun
Finkelstein, Eric Andrew
author_sort Verghese, Naina R.
collection PubMed
description Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relevant examples of implementation differences across countries. In the discussion section, we examine key advantages and disadvantages of each strategy. Methods: A narrative review of the peer-reviewed and grey literature was undertaken to retrieve information, including strategy definitions, practising countries, country-specific implementation considerations, and merits and demerits of each strategy. Results: Seven strategies (Internal Reference Pricing, External Reference Pricing, Special Pricing Agreements, Pharmacoeconomic Evaluation, Cost plus pricing, Price Maintenance Premium, and Tendering and negotiations) were identified as most commonly practised in APAC through the review process. Most countries use multiple strategies that differ in how they are implemented. Conclusion: APAC countries use multiple strategies simultaneously with varying implementation methods, including different formulae and sub-types of medication that a strategy applies to, whether the strategy is a mandate or guideline, and the extent of negotiations and transparency. Strategies are instituted partly with the aim of cost containment, and may also promote price stability, innovation, and increased access in the short and longer term. Abbreviations: APAC - Asia Pacific; WHO - World Health Organisation; IRP - Internal Reference Pricing; ERP - External Reference Pricing; SPA - Special Pricing Agreement; MES - Managed Entry Scheme; PVA - Price-Volume Agreement; RSA - Risk Sharing Agreement; NHIS - National Health Insurance System; PE - Pharmacoeconomic Evaluation; CEA - Cost-Effectiveness Analysis; QALY - Quality-adjusted Life Year; BIA - Budget Impact Analysis; PMP - Price Maintenance Premium; R&D - Research & Development
format Online
Article
Text
id pubmed-6461095
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Routledge
record_format MEDLINE/PubMed
spelling pubmed-64610952019-04-19 Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview Verghese, Naina R. Barrenetxea, Jon Bhargava, Yukti Agrawal, Sagun Finkelstein, Eric Andrew J Mark Access Health Policy Review Article Background and objectives: Governments in Asia Pacific (APAC) are increasingly using pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this narrative review is to discuss formal pricing strategies for reimbursed prescription medication in APAC, supported by relevant examples of implementation differences across countries. In the discussion section, we examine key advantages and disadvantages of each strategy. Methods: A narrative review of the peer-reviewed and grey literature was undertaken to retrieve information, including strategy definitions, practising countries, country-specific implementation considerations, and merits and demerits of each strategy. Results: Seven strategies (Internal Reference Pricing, External Reference Pricing, Special Pricing Agreements, Pharmacoeconomic Evaluation, Cost plus pricing, Price Maintenance Premium, and Tendering and negotiations) were identified as most commonly practised in APAC through the review process. Most countries use multiple strategies that differ in how they are implemented. Conclusion: APAC countries use multiple strategies simultaneously with varying implementation methods, including different formulae and sub-types of medication that a strategy applies to, whether the strategy is a mandate or guideline, and the extent of negotiations and transparency. Strategies are instituted partly with the aim of cost containment, and may also promote price stability, innovation, and increased access in the short and longer term. Abbreviations: APAC - Asia Pacific; WHO - World Health Organisation; IRP - Internal Reference Pricing; ERP - External Reference Pricing; SPA - Special Pricing Agreement; MES - Managed Entry Scheme; PVA - Price-Volume Agreement; RSA - Risk Sharing Agreement; NHIS - National Health Insurance System; PE - Pharmacoeconomic Evaluation; CEA - Cost-Effectiveness Analysis; QALY - Quality-adjusted Life Year; BIA - Budget Impact Analysis; PMP - Price Maintenance Premium; R&D - Research & Development Routledge 2019-04-11 /pmc/articles/PMC6461095/ /pubmed/31007877 http://dx.doi.org/10.1080/20016689.2019.1601060 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Verghese, Naina R.
Barrenetxea, Jon
Bhargava, Yukti
Agrawal, Sagun
Finkelstein, Eric Andrew
Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title_full Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title_fullStr Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title_full_unstemmed Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title_short Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
title_sort government pharmaceutical pricing strategies in the asia-pacific region: an overview
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461095/
https://www.ncbi.nlm.nih.gov/pubmed/31007877
http://dx.doi.org/10.1080/20016689.2019.1601060
work_keys_str_mv AT verghesenainar governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview
AT barrenetxeajon governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview
AT bhargavayukti governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview
AT agrawalsagun governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview
AT finkelsteinericandrew governmentpharmaceuticalpricingstrategiesintheasiapacificregionanoverview